Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | FTO | Q9C0B1 | 9/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552638 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3426429 | 0.83 | FTO (0.59) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5421832 | 0.83 | MAPT (0.67) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5411973 | 0.83 | FTO (0.58) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6244972 | 0.83 | FTO (0.69) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL14713464 | 0.81 | MAPT (0.72) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2285435 | 0.80 | MAPT (0.89) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Fluorescein SCHEMBL11135740 | 0.79 | FTO (0.89) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Fluorescein SCHEMBL991336 | 0.79 | FTO (0.89) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Fluorescein SCHEMBL106710 | 0.79 | FTO (0.89) | MAPTMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642256-B2 | Kinase and ubiquination assays | Life Technologies Corporation (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2221385-A2 | Deubiquination assays | Life Technologies Corporation (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100151484-A1 | KINASE AND UBIQUINATION ASSAYS | Life Technologies Corporation (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1955071-A4 | KINASE AND UBIQUINATION ASSAYS | INVITROGEN CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1955071-A2 | KINASE AND UBIQUINATION ASSAYS | INVITROGEN CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070264678-A1 | KINASE AND UBIQUINATION ASSAYS | INVITROGEN CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007051207-A2 | KINASE AND UBIQUINATION ASSAYS | INVITROGEN CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151484-A1 | KINASE AND UBIQUINATION ASSAYS | COQ8A, DEK, CKMT1A; CKMT1B | KCNH2 3216/4885MAPT 1432/4885MEN1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.